Investigating how miRNAs modulate HER2 and HR signaling could provide critical insights into the molecular basis of tumor heterogeneity and therapy resistance, ultimately informing the development of more effective and personalized strategies for patients with HER2-low breast cancer. The gene discussed is ERBB2; the disease is neoplasm.